• 1
    Gloor JM, DeGoey SR, Pineda AA et al. Overcoming a positive crossmatch in living donor kidney transplantation. Am J Transplant 2003; 3: 10171023.
  • 2
    Glotz D, Antoine C, Julia P et al. Desensitization and subsequent kidney transplantation of patients using intravenous immunoglobulin. Am J Transplant 2002; 2: 758760.
  • 3
    Jordan SC, Vo A, Bunnapradist S et al. Intravenous immune globulin treatment inhibits crossmatch positivity and allows for successful transplantation of incompatible organs in living-donor and cadaver recipients. Transplantation 2003; 76: 631636.
  • 4
    Montgomery RA, Zachary AA, Racusen LC et al. Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients. Transplantation 2000; 70: 887895.
  • 5
    Akalin E, Ames S, Sehgal V et al. Intravenous immunoglobulin and thymoglobulin facilitate kidney transplantation in complement-dependent cytotoxicity B-cell and flow cytometry T- or B-cell crossmatch positive patients. Transplantation 2003; 76: 14441447.
  • 6
    Schweitzer E, Wilson JS, Fernandez-Vina M et al. A high panel-reactive antibody rescue protocol for cross-match-positive live donor kidney transplants. Transplantation 2000; 70: 15311536.
  • 7
    Gloor JM, Lager DJ, Moore SB et al. ABO-incompatible kidney transplantation using both A2 and non-A2 living donors. Transplantation 2003; 75: 971977.
  • 8
    Tanabe K, Takahashi K, Sonda K et al. Long-term results of ABO-incompatible living kidney transplantation. Transplantation 1998; 65: 224228.
  • 9
    Nelson PW, Landreneau MD, Luger AM et al. Ten-year experience in transplantation of A2 kidneys into B and O recipients. Transplantation 1998; 65: 256269.
  • 10
    Lee P-C, Terasaki PI, Takemoto SK et al. All chronic rejection failures of kidney transplants were preceded by the development of HLA antibodies. Transplantation 2003; 74: 11921194.
  • 11
    Racusen LC, Colvin RB, Solez K et al. Antibody-mediated rejection criteria- an addition to the Banff '97 classification of renal allograft rejection. Am J Transplant 2003; 3: 708714.
  • 12
    Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T. The Banff 97 working classification for renal allograft pathology. Kidney Int 1999; 55: 713723.
  • 13
    Gloor JM, DeGoey S, Ploeger N et al. Persistence of low levels of alloantibody after desensitization in crossmatch positive living donor kidney transplantation. Transplantation 2003; 78: 221227.
  • 14
    Wilson DM, Bergert JH, Larson TS, Liedtke RR. GFR determined by nonradiolabeled iothalamate using capillary electrophoresis. Am J Kidney Dis 1997; 30: 646652.
  • 15
    Levey AS, Greene T, Schluchter MD. Glomerular filtration rate measurements in clinical trials. Modification of Diet in Renal Disease Study Group and the Diabetes Control and Complications Trial Research Group. J Am Soc Nephrol 1993; 4: 11591171.
  • 16
    Fidler ME, Gloor JM, Lager DJ et al. Histologic findings of antibody mediated rejection in ABO blood group incompatible living donor kidney transplantation. Am J Transplant 2003; 4: 101107.
  • 17
    Winters JL, Gloor JM, Pineda AA, Stegall MD, Moore SB. Plasma exchange conditioning for ABO-incompatible kidney transplantation. J Clin Apheresis 2004; 19: 17.
  • 18
    Stegall MD, Gloor JM, Winters J, Moore SB. A Comparison of plasmapheresis vs high-dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant 2005; 6: 346351.
  • 19
    Cosio FG, Grande JP, Larson TS et al. Kidney allograft fibrosis and atrophy early after living donor transplantation. Am J Transplant 2005; 5: 17.
  • 20
    Habib R, Broyer M. Clinical significance of allograft glomerulopathy. Kidney Int 1993; 43(Suppl): S95S98.
  • 21
    Monga G, Mazzucco G, Novara R, Reale L. Intertubular capillary changes in kidney allografts: An ultrastructural study in patients with transplant glomerulopathy. Ultrastruct Pathol 1990; 14: 201209.
  • 22
    Cosio FG, Grande JP, Wadei H, Larson TS, Griffin MD, Stegall MD. Predicting subsequent decline in kidney allograft function from early surveillance biopsies. Am J Transplant 2005; 5: 24642472.
  • 23
    Habib R, Zurowska A, Hinglais N et al. A specific glomerular lesion of the graft: Allograft glomerulopathy. Kidney Int 1993; 44(Suppl): S104S111.
  • 24
    Horita S, Nitta K, Kawashima M et al. C4d deposition in the glomeruli and peritubular capillaries associated with transplant glomerulopathy. Clin Transplant 2003; 17: 325330.
  • 25
    Slipkens YW, Joosten SA, Wong M-C et al. Immunologic risk factors and glomerular C4d deposits in chronic transplant glomerulopathy. Kidney Int 2004; 65: 24092418.
  • 26
    Shimmura H, Tanabe K, Ishikawa N, Tokumoto T, Takahashi K, Toma H. Role of anti-A/B antibody titers in results of ABO-incompatible kidney transplantation. Transplantation 2000; 70: 13311335.
  • 27
    Shimmura H, Tanabe K, Ishida H et al. Lack of correlation between results of ABO-incompatible living kidney transplantation and anti-ABO blood type antibody titers under our current immunosuppression. Transplantation 2005; 80: 985988.
  • 28
    Gloor JM, Lager DJ, Fidler ME et al. A comparison of splenectomy versus intensive posttransplant antidonor blood group antibody monitoring without splenectomy in ABO-incompatible kidney transplantation. Transplantation 2005; 80: 15721577.
  • 29
    Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999; 340: 227228.
  • 30
    Saadi S, Platt JL. Immunology of xenotransplantation. Life Sci 1998; 62: 365387.
  • 31
    Park WD, Grande JP, Ninova D et al. Accommodation in ABO-incompatible kidney allografts. Am J Transplant 2003; 3: 952.
  • 32
    Bach FH, Ferran C, Hechenleitner P et al. Accommodation of vascularized xenografts: Expression of “protective genes” by donor endothelial cells in a host Th2 cytokine environment. Nat Med 1997; 3: 196204.
  • 33
    Salama AD, Delikouras A, Pusey CD et al. Transplant accommodation in highly sensitized patients: A potential role for Bcl-xL and alloantibody. Am J Transplant 2001; 1: 260269.